HC Wainwright Maintains Buy Rating on Actinium Pharmaceuticals, Keeps $4 Target
HC Wainwright kept its $4 price target; the target implies 168.5% upside from the Nov. 16 close of $1.49.
HC Wainwright kept its $4 price target; the target implies 168.5% upside from the Nov. 16 close of $1.49.